Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda

Executive Summary

A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.
Advertisement

Related Content

Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr Fluoxetine Sells $175 Mil. For Quarter; Par Has 22% Of 20 Mg Generics
Upsher Launches K-Dur Generic With Exclusivity; FTC Hearing In December
House Medicare Rx Bill Could Be Ready For Floor Vote In October
Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.
Barr Generic Tambocor Launch Planned For Fall Following Win In Patent Case
Barr Generic Tambocor Launch Planned For Fall Following Win In Patent Case
Advertisement
UsernamePublicRestriction

Register

PS038455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel